CECPAR Centro de Estudos Clinicos do Parana

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease3 trials

Phase

• Phase 32 trials
• Phase 2/31 trial

Status

• Recruiting2 trials
• Enrolling by invitation1 trial

Lead sponsor

• ACADIA Pharmaceuticals Inc.2 trials
• Bristol-Myers Squibb1 trial

Running trials

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Phase 3· Bristol-Myers Squibb· Source

  Contact: Luiz Petry, Site 1053

• Enrolling by invitation

  ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

  NCT06194799· Phase 3· ACADIA Pharmaceuticals Inc.· Source

• Recruiting

  ACP-204 in Adults With Alzheimer's Disease Psychosis

  NCT06159673· Phase 2/3· ACADIA Pharmaceuticals Inc.· Source

  Contact: Christine Murphy

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease3 recruiting